ARTES Biotechnology is a leading contract development and manufacturing organisation (CDMO), specialising in the development of microbial cell lines and processes for recombinant protein production. The company leverages its proprietary technologies to support the pharmaceutical industry in bringing high-quality products to market efficiently.

ARTES Biotechnology offers a wide range of services focused on the development and manufacturing of recombinant proteins. With expertise in microbial cell line and process development, the company partners with clients to enhance the speed and cost-effectiveness of bringing innovative therapies to market.

Key Products and Services

• Microbial cell line development (Hansenula polymorpha, E. coli)
• Process development for recombinant proteins
• Manufacturing of test and preclinical material
• Vaccine development
• Licensing of ready-to-use processes for biosimilars, vaccines, and enzymes
• Technology transfer and proprietary cell line licensing
• Recombinant antigens, enzymes, and functional proteins as research reagents

ARTES Biotechnology stands out for its commitment to delivering innovative solutions in biotechnology, helping clients reduce development time and improve the reliability of their products. With proven success in meeting regulatory standards, the company continues to drive advancements in recombinant protein technology.